Risk of Post-COVID Conditions among adolescents and adults who received nirmatrelvir-ritonavir for acute COVID-19: a retrospective cohort study
Preprint
Abstract
Introduction: Post-COVID Conditions (PCC) potentially affect millions of people, but it is unclear whether treating acute COVID-19 with nirmatrelvir-ritonavir may reduce the risk of PCC. Methods: Retrospective cohort study using real-world, closed claims data to assess the relationship between nirmatrelvir-ritonavir and PCC by age group (12-17, 18-49, 50-64, ≥65 years). Eligible patients had a COVID-19 index date (positive laboratory test, ICD-10 diagnosis code, or nirmatrelvir-ritonavir prescription) from April 1 – August 31, 2022, in the outpatient, telehealth, or emergency department setting, and had a higher risk of severe COVID-19 based on age (≥50 years) or underlying risk factors. Treated patients (i.e., received a nirmatrelvir-ritonavir prescription within +/-5 days of index date) were matched 1:2 on age, sex, month of index date, and HHS region with untreated patients. PCC was defined by the presence of ≥1 of 45 new-onset symptoms or conditions recorded ≥60 days after index date. Results: 291,433 treated patients were matched to 582,866 untreated patients. Treatment with nirmatrelvir-ritonavir reduced PCC risk in adults 50-64 years (aHR 0.93, 95%CI 0.92-0.95) and ≥65 years (aHR 0.88, 95% CI 0.87-0.90). Treatment had minimal effect among high-risk adults 18-49 years (aHR 0.98, 95% CI 0.97-0.99), and no effect among high-risk adolescents 12-17 years (aHR 1.06, 95% CI 0.66-1.13). Conclusion: Results using real-world data suggest a protective relationship between nirmatrelvir-ritonavir during acute illness and PCC risk among older adults, but not among adolescents. Consideration may be given to outpatient treatment of mild to moderate COVID-19 with nirmatrelvir-ritonavir to reduce the risk of severe disease and PCC.Keywords
This publication has 27 references indexed in Scilit:
- Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 InfectionJAMA Internal Medicine, 2024
- Association of nirmatrelvir for acute SARS‐CoV‐2 infection with subsequent Long COVID symptoms in an observational cohort studyJournal of Medical Virology, 2024
- Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing HomesJAMA, 2023
- Paxlovid reduces the risk of Long COVID in patients six months after hospital dischargeJournal of Medical Virology, 2023
- Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 ConditionJAMA Internal Medicine, 2023
- Efficacy of nirmatrelvir and ritonavir for post‐acute COVID‐19 sequelae beyond 3 months of SARS‐CoV‐2 infectionJournal of Medical Virology, 2023
- Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care systemThe Lancet Infectious Diseases, 2023
- Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysisJournal of Medical Virology, 2023
- Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2JAMA Network Open, 2022
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987